Specializing in AI-driven deal sourcing, valuation models, 340B strategy, and full-cycle advisory for health systems, PE firms, and pharmacy operators navigating today’s evolving landscape.
End-to-end M&A advisory designed for the complexity of health system pharmacy transactions — powered by AI-driven analysis and decades of real-world deal experience.
Predictive modeling of script retention, synergies, 340B impacts, and technology-enabled operational efficiencies to deliver accurate, defensible valuations.
Full financial review and risk assessment drawing from Walgreens-scale deal experience to surface hidden value and risk.
Leading term sheets, counteroffers, and closings to achieve above-hurdle IRR outcomes in competitive environments.
Structuring JVs, management agreements, and partnership models between health systems and pharmacy operators.
Ensuring smooth transitions, value capture, and operational optimization after close with 100-day integration roadmaps.
Navigating 340B program evolution, IRA impacts, and regulatory changes as part of deal structuring and ongoing strategy.
We bring institutional-grade advisory capabilities to boutique engagements — with the sector depth, AI tools, and deal experience your transaction demands.
Background in Walgreens-scale pharmacy transactions and health system partnerships — including patient segment isolation, full P&L normalization, and closing deals above IRR hurdles across regional and national health systems.
Proprietary AI tools for rapid valuation modeling, market comp analysis, synergy prediction, and script retention forecasting — delivering insights in days, not weeks.
Deep expertise in 340B program economics, IRA impacts, and evolving specialty pharmacy regulations — critical for accurate deal structuring and defensible valuations in 2026.
Our primary structure is a 3% success fee — we only win when you win. Engagements include a monthly advisory retainer scoped to project complexity. Fee structures are discussed transparently at consultation.
We work with buyers, sellers, and strategic partners across the healthcare pharmacy ecosystem — from regional health systems to national PE platforms.
Outpatient, infusion, and specialty pharmacy divisions seeking to sell, acquire, or structure strategic partnerships with best-in-class operators.
Independent and regional specialty pharmacies exploring growth through acquisition, exit strategies, or hospital system partnership models.
PE sponsors seeking deep sector expertise for platform builds, add-on acquisitions, or portfolio optimization in health system pharmacy.
I-banks seeking specialty pharmacy sector expertise and deal execution support on the buy side, sell side, or fairness opinion engagements.
Payer and PBM organizations evaluating pharmacy asset acquisitions, vertical integration strategies, or network partnership structures.
PSAOs, GPOs, and pharmacy service organizations exploring M&A for growth, market consolidation, or strategic repositioning.
A structured, confidential advisory process — from your first inquiry through a closed deal. Every step is designed to protect your information and maximize your outcome.
Your valuation accuracy depends on the quality of data we analyze together. Here’s exactly what to expect — and how we protect your information at every stage.
Your intake form captures only non-sensitive, high-level details — pharmacy type, approximate revenue range, and transaction interest. No proprietary data is requested or shared at this stage.
We schedule a 30–45 minute call to discuss your situation, goals, and timeline. We’ll share our methodology and a sample valuation framework. This is a no-obligation, no-data conversation focused entirely on fit and strategy.
Before any proprietary data is exchanged, we execute a mutual Non-Disclosure Agreement via secure e-signature. This protects both parties and establishes the confidential foundation required for accurate analysis.
⚠️ We never request sensitive financial, operational, or patient data prior to a signed NDA.Post-NDA, we provide a tailored data request checklist covering script volume and mix, payer contracts, 340B program details, P&L statements, and lease/operational agreements. Our AI-augmented analysis begins here — and we work collaboratively to clarify assumptions and fill data gaps.
We deliver a written preliminary valuation range with key assumptions, 340B impact analysis, script retention modeling, and noted sensitivities — giving you a defensible, data-driven benchmark before any decisions are made.
If you choose to move forward, we formalize the engagement — defining scope, deal strategy, buyer/seller outreach, and full due diligence support through negotiation and close. No pressure or obligation from the valuation audit itself.
Full Advisory Engagement Timeline
Form submission, discovery call, and mutual NDA execution — before any sensitive data is shared.
AI-augmented valuation model, 340B analysis, and tailored deal strategy with your leadership team.
Confidential buyer/seller identification, AI-powered deal sourcing, and structured outreach management.
Full P&L normalization, patient segment review, payer contract analysis, and risk quantification.
LOI structuring, counteroffers, closing coordination, and post-close integration planning.
Thought leadership, market intelligence, and practical tools for healthcare finance executives navigating pharmacy M&A in 2026.
PwC and sector data on why specialty pharmacy is one of the hottest M&A subsectors in healthcare — and what it means for valuations, deal timelines, and buyer appetite in the current market.
How IRA changes and 340B program evolution are reshaping deal terms, valuation models, and due diligence requirements for covered entities and contract pharmacies navigating transactions today.
Get a preliminary, AI-powered valuation range for your pharmacy asset — no commitment, no cost. Includes script retention modeling, 340B impact assessment, and a market comp summary delivered to you directly.
On-demand session covering AI-enhanced deal sourcing, predictive modeling methodologies, and what PE firms and health systems are prioritizing in pharmacy asset transactions in the current deal environment.
Whether you’re exploring a sale, seeking an acquisition, or need strategic advisory support — we’re ready to help. All inquiries are handled confidentially.
We’ve received your Free Valuation Audit request and appreciate you reaching out to Meridian Rx Advisors™.
Here’s what to expect next:
Questions in the meantime? Email us at matthewjohnson@meridianrxadvisors.com
We’ve received your inquiry and appreciate you contacting Meridian Rx Advisors™. A member of our team will review your message and respond within 24 business hours.
Need an immediate response? Email us directly at matthewjohnson@meridianrxadvisors.com
We’ve received your Pilot Engagement request and are excited about the opportunity to work together. Here’s what to expect:
Questions? Email us at matthewjohnson@meridianrxadvisors.com